Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ascletis Says China Accepts IND Filing for Novel NASH Treatment

publication date: Feb 18, 2020

Ascletis Pharma, a Hangzhou antiviral company, has filed an IND with China's NMPA for ASC41, a self-developed Category 1 treatment for NASH. Ascletis expects to combine ASC41 with ASC40, another novel Ascletis product, in trials. ASC41 is an oral thyroid hormone receptor beta (THR-beta) agonist, while ASC40 is an oral fatty acid synthase (FASN) inhibitor. In 2018, Ascletis' Ganovo®, an innovative t NS3/4A protease treatment for hepatitis C, was approved for China use, the first approved direct-acting anti-viral agent developed by a China company. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China